Navigation Links
Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
Date:2/5/2008

PRINCETON, N.J., Feb. 5 /PRNewswire/ -- Celator Pharmaceuticals today announced that Andrew Janoff, Ph.D., chief executive officer, is scheduled to present on the company's business operations and clinical development programs at the 10th Annual Biotechnology Industry Organization (BIO) CEO and Investor Conference on Tuesday, February 12, 2008 at 9:30am ET at the Waldorf-Astoria in New York City.

About Celator

Celator Pharmaceuticals, Inc., is a privately held pharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex(TM), the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on identifying a fixed, synergistic ratio of the drugs pre-clinically, incorporating that ratio in a drug delivery vehicle and maintaining the ratio in patients. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan: floxuridine), currently in a Phase 2 trial in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine: daunroubicin), currently in a Phase 1 trial in patients with leukemia; CPX 571 (a liposomal formulation of irinotecan: cisplatin), now positioned to advance to Phase 1; and multiple early stage pre-clinical development programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at http://www.celatorpharma.com.


'/>"/>
SOURCE Celator Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
2. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
3. Anthera Pharmaceuticals Forms Scientific Advisory Board
4. Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
5. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
7. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
8. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
9. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
10. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
11. Access Pharmaceuticals Announces $2.7 Million New Equity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 20, 2017 Ginkgo Bioworks, the organism ... pioneer in the synthesis and assembly of DNA. ... assembling pathway-length synthetic DNA into Ginkgo,s automated organism ... the construction of new organism designs for application ... "Gen9 was founded to significantly increase the world,s ...
(Date:1/19/2017)... HOUSTON , Jan. 19, 2017 ... formation of its Medical/Clinical Advisory Board.  This new ... who enhance the range and depth of expertise ... its novel prenatal diagnostic tests.  These experts are ... guidance for the company,s product development and commercialization ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, ... Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious ... agreement for the merger of PharmAthene and Altimmune ... Novartis Venture Fund, HealthCap, Truffle Capital and Redmont ... and diversified immunotherapeutics company with four clinical stage ...
(Date:1/19/2017)... , ... January 19, 2017 , ... FireflySci Inc. is ... rate. The tremendous growth is accounted to two main factors. The first ... the expanding network of vendors supplying FireflySci products all around the world. , 2016 ...
Breaking Biology Technology:
(Date:12/22/2016)... -- SuperCom (NASDAQ:   SPCB ... Public Safety, HealthCare, and Finance sectors announced today that Leaders in ... implement and deploy a community-based supportive services program to reduce recidivism ... further expanding its presence in the state. ... This new program, which is expected to ...
(Date:12/19/2016)... y TORONTO , 19 de diciembre de 2016 ... Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado ... tipos de tumor en 2017, con múltiples sitios previstos a lo ... ... objetivo en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica ...
(Date:12/16/2016)... 2016 The global wearable medical device market, in terms ... from USD 5.31 billion in 2016, at a CAGR of 18.0% ... ... advancements in medical devices, launch of a growing number of smartphone-based ... among healthcare providers, and increasing focus on physical fitness. ...
Breaking Biology News(10 mins):